Tekturna Articles
Novartis cuts jobs, takes $1.22 billion charges
13 January 2012
EMA reviewing Novartis aliskiren-containing drugs
23 December 2011
Novartis to drop Rasilez/Tekturna in high-risk patients with diabetes and renal impairment
21 December 2011
Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal
27 January 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Novartis to buy Corthera for $120 million, plus up to $500 million on success of ADHF drug relaxin
23 December 2009
Fixed-dose antihypertensive cannot stem tide of patent expiries
4 September 2009
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
Novartis highlights Tekturna's kidney-health benefit
16 March 2009
CHMP asks for angioedema warning on aliskiren label
2 March 2009
PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app
12 January 2009
Novartis speeds R&D ahead of Diovan loss
12 January 2009
CHMP gives nod to four new drugs at meeting
1 December 2008
Novartis lines up aliskiren combos and cancer drugs to deal with Diovan's 2012 patent loss
24 November 2008
Swissmedic approves Novartis
3 November 2008
Novartis profit up 32% in 3rd qtr
27 October 2008
Novartis buys further 51.7% of Speedel
14 July 2008
Tekturna sales harmed by Novartis shakeup?
23 June 2008
Stock Commentary - Europe - week to June 9, 2008
16 June 2008
Speedel earned $2.4M in 1st-qtr 2008
2 June 2008
Tekturna combo "twice as effective" as solo HCT
26 May 2008
Speedel's 1st-qtr 2008 revenues disappoint
26 May 2008
Speedel's 2007 loss down 19.2% on sales
17 March 2008
US physician survey finds big differences in Rx patterns between cardiologists and PCPs
4 February 2008
Novartis' Tekturna HCT cleared by FDA
28 January 2008
US new drug approvals hit 24-year low
14 January 2008
Speedel eligible for royalties from Novartis
10 December 2007
Stock Commentary - Europe - week to Dec 3, 2007
10 December 2007
Tekturna helps Speedel narrow 3rd-qtr 2007 loss
26 November 2007
Teturna cuts level of proteinuria in diabetics
19 November 2007
Novartis to invest 300M CHFs in drug plant
3 September 2007
Speedel's 2nd-qtr net loss exceeds predictions
3 September 2007
EMEA clears Rasilez for high blood pressure
3 September 2007
SPP635 successful in hypertension study
9 July 2007
Exforge cuts mean bp 20mmHg in Ph III trial
28 May 2007
Speedel's 1st-qtr 2007 loss falls to $12.2M
14 May 2007
Stock Commentary - Europe - week to April 9
16 April 2007
Speedel's 2006 loss up 39%, on R&D costs
9 April 2007
Novartis' Tekturna and Diovan work in synergy
2 April 2007
Stock Commentary - Europe - week to March 12, 2007
26 March 2007
Stock Commentary - Europe - week to March 5, 2007
12 March 2007
Novartis and Speedel
12 March 2007
Speedel starts Ph I SPP1148 testing
22 January 2007
3 month delay in US review of Novartis and Speedel's first-in-class BP drug Tekturna
22 December 2006
Speedel initiates Ph IIa trial of SPP635
6 November 2006
Showing 1-56 of 56 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
